PL2215121T3 - Przeciwciała przeciwko mezotelinie i ich zastosowania - Google Patents
Przeciwciała przeciwko mezotelinie i ich zastosowaniaInfo
- Publication number
- PL2215121T3 PL2215121T3 PL08855189T PL08855189T PL2215121T3 PL 2215121 T3 PL2215121 T3 PL 2215121T3 PL 08855189 T PL08855189 T PL 08855189T PL 08855189 T PL08855189 T PL 08855189T PL 2215121 T3 PL2215121 T3 PL 2215121T3
- Authority
- PL
- Poland
- Prior art keywords
- uses therefor
- mesothelin antibodies
- mesothelin
- antibodies
- therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US437807P | 2007-11-26 | 2007-11-26 | |
| PCT/EP2008/009756 WO2009068204A1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
| EP08855189.0A EP2215121B1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2215121T3 true PL2215121T3 (pl) | 2016-07-29 |
Family
ID=40351874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08855189T PL2215121T3 (pl) | 2007-11-26 | 2008-11-19 | Przeciwciała przeciwko mezotelinie i ich zastosowania |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US9023351B2 (pl) |
| EP (3) | EP2634196A1 (pl) |
| JP (3) | JP5608091B2 (pl) |
| KR (1) | KR101559599B1 (pl) |
| CN (2) | CN104151429B (pl) |
| AU (1) | AU2008329221B2 (pl) |
| BR (1) | BRPI0819909B8 (pl) |
| CA (1) | CA2706529C (pl) |
| CO (1) | CO6280409A2 (pl) |
| CR (1) | CR11456A (pl) |
| CU (1) | CU23833A3 (pl) |
| CY (1) | CY1117437T1 (pl) |
| DK (1) | DK2215121T3 (pl) |
| DO (1) | DOP2010000150A (pl) |
| EC (1) | ECSP10010191A (pl) |
| ES (1) | ES2569513T3 (pl) |
| GT (1) | GT201000148A (pl) |
| HK (2) | HK1148541A1 (pl) |
| HN (1) | HN2010001062A (pl) |
| HR (1) | HRP20160485T1 (pl) |
| HU (1) | HUE027358T2 (pl) |
| IL (1) | IL205681A0 (pl) |
| MA (1) | MA31862B1 (pl) |
| MX (1) | MX2010005603A (pl) |
| MY (1) | MY157164A (pl) |
| NZ (1) | NZ585551A (pl) |
| PL (1) | PL2215121T3 (pl) |
| SI (1) | SI2215121T1 (pl) |
| TN (1) | TN2010000234A1 (pl) |
| UA (1) | UA106036C2 (pl) |
| WO (1) | WO2009068204A1 (pl) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101554753B1 (ko) * | 2007-10-01 | 2015-09-22 | 브리스톨-마이어스 스큅 컴퍼니 | 메소텔린에 결합하는 인간 항체 및 이의 용도 |
| DK2215121T3 (en) * | 2007-11-26 | 2016-05-02 | Bayer Ip Gmbh | ANTI-mesothelin ANTIBODIES AND USES THEREOF |
| AR076284A1 (es) * | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| MA34881B1 (fr) | 2010-12-20 | 2014-02-01 | Genentech Inc | Anticorps et immunoconjugués anti-mésothéline |
| AU2012228100B2 (en) | 2011-03-17 | 2016-09-08 | The University Of Birmingham | Re-directed immunotherapy |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| RU2013151599A (ru) | 2011-04-21 | 2015-05-27 | Сиэтл Дженетикс, Инк. | Новые конъюгаты связывающее соединение-активное соединение (adc) и их применение |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| ES2666131T3 (es) * | 2012-09-27 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos de mesotelina y métodos para provocar una potente actividad antitumoral |
| CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
| JP6721507B2 (ja) | 2013-12-23 | 2020-07-15 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ） |
| BR112017006598A2 (pt) * | 2014-09-30 | 2018-04-17 | Neurimmune Holding Ag | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| JP2018515123A (ja) | 2015-05-18 | 2018-06-14 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| KR20180018808A (ko) | 2015-06-22 | 2018-02-21 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) 및 항체 전구약물 접합체 (apdc) |
| US20180193456A1 (en) * | 2015-06-30 | 2018-07-12 | Henlius Biotech Co., Ltd. | Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies |
| JP6994456B2 (ja) * | 2015-08-21 | 2022-02-04 | カファ セラピューティクス リミテッド | 抗メソテリン完全ヒト抗体およびメソテリンを標的とする免疫エフェクター細胞 |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| CN109069597A (zh) | 2015-12-22 | 2018-12-21 | 诺华股份有限公司 | 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗 |
| KR20180099768A (ko) | 2015-12-30 | 2018-09-05 | 노파르티스 아게 | 증진된 효능을 갖는 면역 이펙터 세포 요법 |
| US12123876B2 (en) | 2016-02-15 | 2024-10-22 | Kanagawa Prefectural Hospital Organization | Antibody binding to HEG1 and use of the antibody for detection and treatment of mesothelioma |
| AU2017225733A1 (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| CN108883195A (zh) | 2016-03-24 | 2018-11-23 | 拜耳制药股份公司 | 具有酶促可裂解基团的细胞毒性活性物质的前药 |
| SG11201809041TA (en) | 2016-04-15 | 2018-11-29 | Novartis Ag | Compositions and methods for selective protein expression |
| CN109476747A (zh) | 2016-05-27 | 2019-03-15 | 艾伯维生物制药股份有限公司 | 结合免疫调节性蛋白和肿瘤抗原的双特异性结合蛋白 |
| CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
| US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
| WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| CN112280796A (zh) | 2016-10-07 | 2021-01-29 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
| WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US10736976B2 (en) | 2016-12-01 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| EP3558388A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| EP3558386A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3638295A1 (en) | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP6339283B1 (ja) | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| JP7489316B2 (ja) | 2017-12-19 | 2024-05-23 | エフ－スター セラピューティクス リミテッド | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 |
| EA202091488A1 (ru) * | 2017-12-24 | 2020-09-23 | Нойл-Иммьюн Байотек, Инк. | Иммунокомпетентная клетка, которая экспрессирует молекулу клеточной поверхности, специфически распознающую человеческий мезотелин, il-7 и ccl19 |
| CN112638932A (zh) | 2018-04-27 | 2021-04-09 | 比奥根Ma公司 | 人源性抗(聚-ga)二肽重复序列(dpr)抗体 |
| US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| MX2021002225A (es) | 2018-08-30 | 2021-07-16 | Tcr2 Therapeutics Inc | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. |
| EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
| MX2021007392A (es) | 2018-12-20 | 2021-08-24 | Novartis Ag | Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
| EA202192029A1 (ru) | 2019-02-15 | 2021-10-27 | Новартис Аг | Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения |
| CA3132771A1 (en) * | 2019-03-14 | 2020-09-17 | Morphosys Ag | Antibodies targeting c5ar |
| EA202192555A1 (ru) | 2019-03-19 | 2021-11-25 | Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн | Комбинированная терапия для лечения рака |
| WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
| WO2021021825A1 (en) * | 2019-07-29 | 2021-02-04 | Fred Hutchinson Cancer Research Center | Methods and compositions for inducing notch signaling in tumor microenvironments |
| AU2020405230A1 (en) | 2019-12-20 | 2022-06-23 | Amgen Inc. | Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
| IL298262A (en) | 2020-06-23 | 2023-01-01 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
| WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN116019939A (zh) * | 2022-11-24 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 靶向msln的分子探针以及用途 |
| WO2024226827A2 (en) | 2023-04-25 | 2024-10-31 | Arsenal Biosciences, Inc. | Novel receptors for transcription regulation |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| WO2024251846A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with mek inhibitors for the treatment of cancer |
| WO2024251854A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with braf inhibitors for the treatment of cancer |
| CN117843793B (zh) * | 2024-03-07 | 2024-07-09 | 深圳真实生物医药科技有限公司 | 抗间皮素抗体、抗原结合片段及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| US6083502A (en) | 1996-01-05 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mesothelium antigen and methods and kits for targeting it |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| EP1025230B1 (en) | 1997-12-01 | 2006-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
| EP1169645B1 (en) * | 1999-02-26 | 2006-05-31 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| JP4312403B2 (ja) | 1999-07-20 | 2009-08-12 | モルフォシス・アクチェンゲゼルシャフト | （ポリ）ペプチド／タンパク質を、ジスルフィド結合を介してバクテリオファージ粒子に表示させる新規方法 |
| EP2322560B1 (en) * | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| EP1885758A2 (en) * | 2005-05-12 | 2008-02-13 | The Government of the United States of America as Represented by The Department of Health and Human Services | Anti-mesothelin antibodies useful for immunological assays |
| BRPI0610796B8 (pt) | 2005-05-18 | 2021-05-25 | Morphosys Ag | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo |
| CA2610234A1 (en) * | 2005-06-02 | 2006-12-07 | Astrazeneca Ab | Antibodies directed to cd20 and uses thereof |
| KR101554753B1 (ko) * | 2007-10-01 | 2015-09-22 | 브리스톨-마이어스 스큅 컴퍼니 | 메소텔린에 결합하는 인간 항체 및 이의 용도 |
| DK2215121T3 (en) * | 2007-11-26 | 2016-05-02 | Bayer Ip Gmbh | ANTI-mesothelin ANTIBODIES AND USES THEREOF |
-
2008
- 2008-11-19 DK DK08855189.0T patent/DK2215121T3/en active
- 2008-11-19 NZ NZ585551A patent/NZ585551A/en unknown
- 2008-11-19 BR BRPI0819909A patent/BRPI0819909B8/pt active IP Right Grant
- 2008-11-19 CN CN201410396441.8A patent/CN104151429B/zh active Active
- 2008-11-19 CA CA2706529A patent/CA2706529C/en active Active
- 2008-11-19 UA UAA201008006A patent/UA106036C2/uk unknown
- 2008-11-19 EP EP13168583.6A patent/EP2634196A1/en not_active Ceased
- 2008-11-19 WO PCT/EP2008/009756 patent/WO2009068204A1/en active Application Filing
- 2008-11-19 EP EP08855189.0A patent/EP2215121B1/en active Active
- 2008-11-19 ES ES08855189.0T patent/ES2569513T3/es active Active
- 2008-11-19 AU AU2008329221A patent/AU2008329221B2/en active Active
- 2008-11-19 HU HUE08855189A patent/HUE027358T2/en unknown
- 2008-11-19 KR KR1020107011375A patent/KR101559599B1/ko active IP Right Grant
- 2008-11-19 CN CN200880125390.8A patent/CN101952319B/zh active Active
- 2008-11-19 PL PL08855189T patent/PL2215121T3/pl unknown
- 2008-11-19 EP EP16170412.7A patent/EP3103814A1/en not_active Withdrawn
- 2008-11-19 MX MX2010005603A patent/MX2010005603A/es active IP Right Grant
- 2008-11-19 SI SI200831603A patent/SI2215121T1/sl unknown
- 2008-11-19 JP JP2010535269A patent/JP5608091B2/ja active Active
- 2008-11-19 US US12/744,849 patent/US9023351B2/en active Active
- 2008-11-19 MY MYPI2010002379A patent/MY157164A/en unknown
-
2010
- 2010-05-11 IL IL205681A patent/IL205681A0/en active IP Right Grant
- 2010-05-20 DO DO2010000150A patent/DOP2010000150A/es unknown
- 2010-05-20 GT GT201000148A patent/GT201000148A/es unknown
- 2010-05-21 CR CR11456A patent/CR11456A/es unknown
- 2010-05-21 EC EC2010010191A patent/ECSP10010191A/es unknown
- 2010-05-21 HN HN2010001062A patent/HN2010001062A/es unknown
- 2010-05-21 CO CO10061059A patent/CO6280409A2/es not_active Application Discontinuation
- 2010-05-21 CU CU2010000098A patent/CU23833A3/es active IP Right Grant
- 2010-05-24 MA MA32865A patent/MA31862B1/fr unknown
- 2010-05-25 TN TN2010000234A patent/TN2010000234A1/fr unknown
-
2011
- 2011-03-16 HK HK11102654.0A patent/HK1148541A1/xx unknown
-
2014
- 2014-07-03 JP JP2014137893A patent/JP2014221064A/ja active Pending
-
2015
- 2015-02-10 HK HK15101434.5A patent/HK1200856A1/xx unknown
- 2015-03-11 US US14/645,411 patent/US20150259433A1/en not_active Abandoned
-
2016
- 2016-04-27 CY CY20161100353T patent/CY1117437T1/el unknown
- 2016-05-06 HR HRP20160485TT patent/HRP20160485T1/hr unknown
-
2018
- 2018-03-05 JP JP2018038254A patent/JP6717869B2/ja active Active
- 2018-03-05 US US15/911,748 patent/US20180258181A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL205681A0 (en) | Anti-mesothelin antibodies and uses therefor | |
| HRP20180596T1 (hr) | PROTUTIJELA PROTIV Sp35 I NJIHOVA UPOTREBA | |
| IL200012A0 (en) | Anti-robo4 antibodies and uses therefor | |
| HK1142341A1 (en) | Anti-hepcidin antibodies and uses thereof | |
| PL2099826T3 (pl) | Przeciwciało przeciwko beta-amyloidowi i jego zastosowania | |
| HK1208228A1 (en) | Antibodies and immunoconjugates and uses therefor | |
| ZA200810311B (en) | Anti-NKG2A antibodies and uses thereof | |
| HK1182721A1 (zh) | 抗體和免疫偶聯物及其用途 | |
| IL209309A0 (en) | Anti-fn14 antibodies and uses thereof | |
| EP2185692A4 (en) | HCO32 AND HCO27 AND RELATED EXAMPLES | |
| ZA200809776B (en) | Antibodies and immunoconjugates and uses therefor | |
| IL216731A (en) | And antibodies against p95 – her2 and their uses | |
| SI2061814T1 (sl) | Protitelesa in imunokonjugati in njihove uporabe | |
| HK1203206A1 (en) | Antibody and use thereof | |
| ZA200905136B (en) | Anti-robo4 antibodies and uses therefor | |
| GB0711398D0 (en) | Substituted organpolysiloxanes and uses thereof |